Marshall Wace, LLP Adagio Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
A detailed history of Marshall Wace, LLP transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 754,907 shares of ADGI stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
754,907
Previous 29,411
2466.75%
Holding current value
$2.5 Million
Previous $97,000
2475.26%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ADGI
# of Institutions
94Shares Held
64MCall Options Held
828KPut Options Held
23.4K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11.8MShares$38.9 Million0.77% of portfolio
-
Deep Track Capital, LP Greenwich, CT11MShares$36.3 Million1.2% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million28.73% of portfolio
-
Alphabet Inc. Mountain View, CA4.53MShares$15 Million0.66% of portfolio
-
Slate Path Capital LP New York, NY3.74MShares$12.4 Million0.25% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...